- You can view the full Optimer Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
Stock futures are little changed Wednesday despite upbeat reports on GDP and jobs ahead of the Fed announcement.
Cubist announces two acquisitions in one day.